AngioDynamics gets FDA OK for prostate cancer study

06/20/2013 | MedGadget.com

AngioDynamics has received investigational device exemption approval from the FDA to conduct a clinical study of its NanoKnife technology, which uses precise ablation to treat patients with localized prostate cancer. The trial will enroll 200 patients from six clinical sites in Europe.

View Full Article in:

MedGadget.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA